Invivyd, Inc.
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.
On February 14, 2022, Tillman Gerngross, Ph.D. communicated to the Chairperson of the Board of Directors (the “Board”) of Adagio Therapeutics, Inc. (the “Company”) that he agreed in principle to resign from his position as Chief Executive Officer of the Company.
The Board intends to appoint Mr. David Hering, M.B.A. (who currently serves as the Company’s Chief Operating Officer) as Interim Chief Executive Officer of the Company.
Extracted from this filing and checked against the source text.
Tillman Gerngross resigned as Chief Executive Officer at Invivyd, Inc..
On February 14, 2022, Tillman Gerngross, Ph.D. communicated to the Chairperson of the Board of Directors (the “Board”) of Adagio Therapeutics, Inc. (the “Company”) that he agreed in principle to resign from his position as Chief Executive Officer of the Company.View on SEC.gov
David Hering was appointed as Interim Chief Executive Officer at Invivyd, Inc..
The Board intends to appoint Mr. David Hering, M.B.A. (who currently serves as the Company’s Chief Operating Officer) as Interim Chief Executive Officer of the Company.View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.